| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maria de Fátima Dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, Messias Gonzaga Pereira, Norberto Cysne Coimbr. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders. Basic & clinical pharmacology & toxicology. 2024-03-13. PMID:38477419. |
therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and parkinson's disease and in comorbidity with psychiatric disorders. |
2024-03-13 |
2024-03-15 |
Not clear |
| Kamleshun Ramphul, Renuka Verma, Prince Kwabla Pekyi-Boateng, Hemamalini Sakthive. Growing cannabis use among Multiple Sclerosis adults with chronic pain; An analysis from the United States. Multiple sclerosis and related disorders. vol 82. 2023-12-22. PMID:38134607. |
growing cannabis use among multiple sclerosis adults with chronic pain; an analysis from the united states. |
2023-12-22 |
2023-12-25 |
Not clear |
| Adedeji O Adenusi, Hezborn M Magacha, Chisom M Nwaneki, Olamide A Asifat, Eugene N Anno. Cannabis Use and Associated Gastrointestinal Disorders: A Literature Review. Cureus. vol 15. issue 7. 2023-08-14. PMID:37575784. |
it is widely used for recreational purposes, while its therapeutic benefits have been extensively explored in the us. for several years, cannabis has been used for the treatment of diverse health conditions, including pain management, anti-inflammatory effects, and spasticity associated with multiple sclerosis and other neurodegenerative diseases. |
2023-08-14 |
2023-08-16 |
Not clear |
| Carmen-Adella Sirbu, Ruxandra Georgescu, Florentina Cristina Pleşa, Alina Paunescu, Monica Marilena Ţânţu, Alina Crenguţa Nicolae, Ionut Caloianu, Marian Mitric. Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review. American journal of therapeutics. vol 30. issue 3. 2023-06-06. PMID:37278703. |
cannabis and cannabinoids in multiple sclerosis: from experimental models to clinical practice-a review. |
2023-06-06 |
2023-08-14 |
Not clear |
| Michelle M Rainka, Traci S Aladeen, Anna G Mattle, Emily Lewandowski, Denis Vanini, Katelyn McCormack, Laszlo Mechtle. Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population. International journal of MS care. vol 25. issue 3. 2023-05-30. PMID:37250194. |
multiple sclerosis and use of medical cannabis: a retrospective review of a neurology outpatient population. |
2023-05-30 |
2023-08-14 |
Not clear |
| Kara Link, Lindsey M Knowles, Kevin N Alschuler, Dawn M Ehd. Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: An observational study. Multiple sclerosis and related disorders. vol 75. 2023-05-08. PMID:37156034. |
characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: an observational study. |
2023-05-08 |
2023-08-14 |
Not clear |
| Kara Link, Lindsey M Knowles, Kevin N Alschuler, Dawn M Ehd. Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: An observational study. Multiple sclerosis and related disorders. vol 75. 2023-05-08. PMID:37156034. |
although cannabis has become an increasingly common method for pain management among people with multiple sclerosis (pwms), there is a dearth of knowledge regarding the types of cannabis products used as well as the characteristics of cannabis users. |
2023-05-08 |
2023-08-14 |
Not clear |
| Iddrisu Ibrahim, Soumyakrishnan Syamala, Joseph Atia Ayariga, Junhuan Xu, Boakai K Robertson, Sreepriya Meenakshisundaram, Olufemi S Ajay. Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids. Metabolites. vol 12. issue 12. 2022-12-23. PMID:36557285. |
cannabidiol (cbd) and tetrahydrocannabinol (thc) are used to treat muscle spasticity associated with multiple sclerosis. |
2022-12-23 |
2023-08-14 |
human |
| Elisa Landucci, Costanza Mazzantini, Daniele Lana, Maura Calvani, Giada Magni, Maria Grazia Giovannini, Domenico E Pellegrini-Giampietr. Cannabidiol inhibits microglia activation and mitigates neuronal damage induced by kainate in an in-vitro seizure model. Neurobiology of disease. 2022-10-14. PMID:36240948. |
in the last years the interest on the non-psychoactive compounds present in cannabis sativa has massively increased, and cannabidiol (cbd) has been shown to be effective in the treatment of different types of neurological disorders and neurodegenerative diseases such as epilepsy, ischemia, multiple sclerosis and alzheimer's disease. |
2022-10-14 |
2023-08-14 |
Not clear |
| Bhasker Amatya, Fary Kha. Are cannabis and cannabinoids effective for symptomatic treatment in people with multiple sclerosis? - A Cochrane Review summary with commentary. American journal of physical medicine & rehabilitation. 2022-09-13. PMID:36099645. |
are cannabis and cannabinoids effective for symptomatic treatment in people with multiple sclerosis? |
2022-09-13 |
2023-08-14 |
Not clear |
| Amber Salter, Gary Cutter, Ruth Ann Marrie, Kathryn Nichol, Joshua R Steinerman, Karry M J Smith, Robert J Fo. Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis. Neurology. Clinical practice. vol 12. issue 2. 2022-06-23. PMID:35733947. |
sources of cannabis information and medical guidance for neurologic use: narcoms survey of people living with multiple sclerosis. |
2022-06-23 |
2023-08-14 |
Not clear |
| Yolanda Paes-Colli, Andrey F L Aguiar, Alinny Rosendo Isaac, Bruna K Ferreira, Raquel Maria P Campos, Priscila Martins Pinheiro Trindade, Ricardo Augusto de Melo Reis, Luzia S Sampai. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in cellular neuroscience. vol 16. 2022-06-16. PMID:35707521. |
in clinical practice, cannabis products have already been introduced to treatment regimens of alzheimer's disease, parkinson's disease and multiple sclerosis's patients, and the mechanisms of action behind the reported improvement in the clinical outcome and disease progression are associated with their anti-inflammatory, immunosuppressive, antioxidant, and neuroprotective properties, due to the modulation of the endocannabinoid system. |
2022-06-16 |
2023-08-14 |
Not clear |
| Graziella Filippini, Silvia Minozzi, Francesca Borrelli, Michela Cinquini, Kerry Dwa. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. The Cochrane database of systematic reviews. vol 5. 2022-05-05. PMID:35510826. |
cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. |
2022-05-05 |
2023-08-13 |
Not clear |
| Talia M Santarossa, Randy So, Dr Penelope Smyth, Dr Stefan Gustavsen, Dr Ross T Tsuyuk. Medical cannabis use in Canadians with multiple sclerosis. Multiple sclerosis and related disorders. vol 59. 2022-04-06. PMID:35382939. |
medical cannabis use in canadians with multiple sclerosis. |
2022-04-06 |
2023-08-13 |
Not clear |
| Talia M Santarossa, Randy So, Dr Penelope Smyth, Dr Stefan Gustavsen, Dr Ross T Tsuyuk. Medical cannabis use in Canadians with multiple sclerosis. Multiple sclerosis and related disorders. vol 59. 2022-04-06. PMID:35382939. |
the extent of medical cannabis use by people with multiple sclerosis (ms) in canada has not been evaluated for more than a decade since recreational cannabis was legalized. |
2022-04-06 |
2023-08-13 |
Not clear |
| Victor Longoria, Hannah Parcel, Bameelia Toma, Annu Minhas, Rana Zein. Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. Biomedicines. vol 10. issue 3. 2022-03-25. PMID:35327341. |
neurological benefits, clinical challenges, and neuropathologic promise of medical marijuana: a systematic review of cannabinoid effects in multiple sclerosis and experimental models of demyelination. |
2022-03-25 |
2023-08-13 |
Not clear |
| Jeffrey Landrigan, Kitti Bessenyei, Damian Leitner, Igor Yakovenko, John D Fisk, Jennifer L Prentic. A systematic review of the effects of cannabis on cognition in people with multiple sclerosis. Multiple sclerosis and related disorders. vol 57. 2022-02-15. PMID:35158449. |
a systematic review of the effects of cannabis on cognition in people with multiple sclerosis. |
2022-02-15 |
2023-08-13 |
Not clear |
| Amber Salter, Robert J Fox, Gary Cutter, Ruth Ann Marrie, Kate E Nichol, Joshua R Steinerman, Karry M J Smit. A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. International journal of MS care. vol 23. issue 6. 2022-01-17. PMID:35035295. |
a survey of cannabis use in a large us-based cohort of people with multiple sclerosis. |
2022-01-17 |
2023-08-13 |
Not clear |
| Amber Salter, Robert J Fox, Gary Cutter, Ruth Ann Marrie, Kate E Nichol, Joshua R Steinerman, Karry M J Smit. A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. International journal of MS care. vol 23. issue 6. 2022-01-17. PMID:35035295. |
as cannabis products become increasingly accessible across the united states, it is important to understand the contemporary use of cannabis for managing multiple sclerosis (ms) symptoms. |
2022-01-17 |
2023-08-13 |
Not clear |
| Anthony Feinstein, Cecilia Meza, Cristiana Stefan, W Richard Staine. Discontinuing cannabis improves depression in people with multiple sclerosis: A short report. Multiple sclerosis (Houndmills, Basingstoke, England). vol 27. issue 4. 2021-09-24. PMID:32589554. |
discontinuing cannabis improves depression in people with multiple sclerosis: a short report. |
2021-09-24 |
2023-08-13 |
human |